| 2581 - 2582 |
Introduction: Process chemistry
Lipton MF, Barrett AGM |
| 2583 - 2595 |
Process chemistry: The science, business, logic, and logistics
Zhang TY |
| 2596 - 2616 |
Organolithium reagents in pharmaceutical asymmetric processes
Wu G, Huang MS |
| 2617 - 2650 |
Boron reagents in process chemistry: Excellent tools for selective reductions
Burkhardt ER, Matos K |
| 2651 - 2710 |
Selected patented cross-coupling reaction technologies
Corbet JP, Mignani G |
| 2711 - 2733 |
Crystallization-induced diastereomer transformations
Brands KMJ, Davies AJ |
| 2734 - 2793 |
Asymmetric synthesis of active pharmaceutical ingredients
Farina V, Reeves JT, Senanayake CH, Song JHJ |
| 2794 - 2810 |
Emerging technologies supporting chemical process R&D and their increasing impact on productivity in the pharmaceutical industry
Rubin AE, Tummala S, Both DA, Wang CC, Delaney EJ |
| 2811 - 2827 |
Industrial syntheses of the central core molecules of HIV protease inhibitors
Izawa K, Onishi T |
| 2828 - 2842 |
alpha-aminoalkyl-alpha'-halomethylketones: Preparation and application to pharmaceutically interesting compounds
Reeder MR, Anderson RM |
| 2843 - 2874 |
cis-1-amino-2-indanol in drug design and applications to asymmetric processes
Gallou I, Senanayake CH |
| 2875 - 2911 |
Practical methodologies for the synthesis of indoles
Humphrey GR, Kuethe JT |
| 2912 - 2942 |
High-throughput and parallel screening methods in asymmetric hydrogenation
Jakel C, Paciello R |
| 2943 - 2989 |
Large-scale oxidations in the pharmaceutical industry
Caron P, Dugger RW, Ruggeri SG, Ragan JA, Ripin DHB |
| 2990 - 3001 |
Ozonolysis applications in drug synthesis
Van Ornum SG, Champeau RM, Pariza R |
| 3002 - 3027 |
Critical assessment of pharmaceutical processess - A rationale for changing the synthetic route
Butters M, Catterick D, Craig A, Curzons A, Dale D, Gillmore A, Green SP, Marziano I, Sherlock JP, White W |
